An Immediate Stock Alert is Being Called On:
Algernon Pharmaceuticals Inc.
(OTC: AGNPF) (CSE: AGN)
Keep Reading Below to See Why…
While we’ve seen industries like food delivery, and even gold, benefit from the recent pandemic, no stocks have produced bigger gains for investors than coronavirus penny stocks dealing directly with treating and preventing the virus.
Here are just a few of the many big winners so far:
Novavax rallied over 360% once investors found out it had a compound that might treat COVID-19
Vaxart took off nearly 930% once investors found out it had a flu vaccine applicable to coronavirus.
AIM Immunotech shares skyrocketed over 1,000% when early investors began speculating on its influenza treatment for COVID-19
Alpha Pro Tech exploded nearly 1,100% when early investors figured out that COVID-19 might result in a need for facemasks; they were right!
Allied Healthcare Products jumped 2,900% after early investors figured out that its respirator products could be useful during this pandemic
This Could Be Just the Beginning for Coronavirus Stocks!
What has been the significant factor for making money with coronavirus stocks? Being early. Notice that “early investors” in every case managed to reap the most rewards along the way. The fact that not one but multiple stocks (including many not mentioned here) produced thousands in percentage gains means that there is likely a huge focus on what’s next.
While the first wave of speculation taught us a lot and produced record-setting gains, the next wave of “undiscovered” COVID-19 names could deliver even more.
Again, the key is timing because as we’ve seen from previous pandemics, there’s an optimal window of time to take advantage of; now is that time.
The coronavirus has created a mad panic across the world and by now billions of people not only know what it is but are also well-aware that the healthcare industry is coming together to work on a vaccine or to find a drug treatment.
For investors, the next coronavirus stock to watch is a huge focus and when you talk about timing and opportunity in the market, getting your eyes on the next potential company to break out is key. Like we showed in the examples above, the ones who were early caught the most gains…to the tune of thousand of percentage points. The fact that this wasn’t just from “a couple lucky stocks” is even more of a reinforcement that this is where you need to be looking if your goal is profiting from this race for innovation.
The #1 Rule For Investing is: Buy Low & Sell High!
That couldn’t be more true than right now and the evidence suggests that investors are looking for the next “Buy Low” scenario. While all of the previous coronavirus stocks are trading much higher, are there any left to watch that hasn’t been discovered by the masses yet?
The Answer is… YES!
Companies like Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) are still flying under the radar; but not for long. While the hunt is on with investors constantly scouring the web for any company with “coronavirus” or “COVID-19” as a keyword on major financial sites, Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has only just begun to gain exposure. But it won’t stay “unknown” for long.
Of course, there’s fundamental risk when investing at the early stages of any company, but there is also the potential of GREAT REWARD as we’ve clearly seen!
Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) is a clinical-stage pharmaceutical development company. Its lead compound is a repurposed drug called NP-120 (Ifenprodil). The orally delivered small molecule was originally developed by Sanofi to treat peripheral circulatory disorders.
In one of Algernon’s research programs, Ifenprodil showed promise as a possible treatment for idiopathic pulmonary fibrosis (IPF) and chronic cough. But things completely changed when it was discovered that the drug was effective against the world’s most lethal flu virus H5N1. When tested in an animal study, it reduced mortality by 40%, reduced acute lung injury (ALI) and reduced inflammation in the lungs.
Ifenprodil was also shown in a separate animal study to prolong survival under anoxic (low oxygen) conditions, as might occur in patients with severely impaired lung function.
The connection was simple…if Ifenprodil works that well with H5N1, a virus that has a 50% mortality rate, how effective could it be for COVID-19, which has a 3% fatality rate?
Algernon Could Stand Toe To Toe With Roche, Merck & More
Boehringer Ingelheim’s Nintedanib; and
These were done in a pre-clinical in vivo animal study, reducing fibrosis by 56% with statistical significance. Algernon additionally investigated Ifenprodil in an acute cough animal study where it outperformed Merck’s phase 3 drug Gefapixant by 110%. Since Ifenprodil is already approved with an established safety history, Algernon intends to move the drug directly into a phase II human trial.
The Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) business model is to repurpose safe approved drugs that are not available in the US or Europe, screen them in globally accepted animal models for new diseases, file new intellectual property rights and then move them into an off label phase II trial in the country where they were originally approved. Once a signal is established in a human trial, the company will begin to advance the repurposed drug through a USFDA registration.
Where Does COVID-19 Come Into Play & Why Is Now The Time For Algernon?
Since Ifenprodil’s performance in H5N1 research studies was first discovered, Algernon has been aggressively engaged in advancing it as a potential new therapeutic for COVID-19 patients. The company has already filed a pre-IND (Investigational New Drug) meeting request with the U.S. FDA for the treatment and prevention of ALI and acute respiratory distress syndrome (ARDS) associated with COVID-19 infection. The Company believes that Ifenprodil may reduce the severity and duration of a COVID-19 infection. And in mid-April, the company formally received positive feedback from the U.S. FDA for Ifenprodil.
It has also recently submitted for ethics approval in Australia for its planned Phase 2 study of its Ifenprodil for both IPF and chronic cough.
The company has already received positive feedback from Health Canada on its plan to conduct a phase 2 COVID-19 clinical study in Canada. Based on the feedback, which came from Health Canada’s Office of Clinical Trials Algernon has prepared and submitted a Clinical Trial Application (CTA) to Health Canada for an NP-120 (Ifenprodil) COVID-19 Phase 2b/3 multinational clinical trial.
In addition to advancing Ifenprodil towards a human trial approval in Canada, the Company is has also received approval from the Ministry of Food and Drug Safety in South Korea, as well as ethics approval, for an investigator-led, Phase 2 COVID-19 clinical study of its re-purposed drug NP-120 (Ifenprodil), an NMDA receptor antagonist. This 40-patient trial is designed to test the effect of Ifenprodil in COVID-19 infected patients with severe pneumonia.
Download / View
(OTC: AGNPF) (CSE: AGN)
Corporate Presentation, Below
Why Algernon Pharmaceuticals Inc.
(OTC: AGNPF) (CSE: AGN)
- Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) is one of the few companies still flying under the radar of the masses, potentially giving one of the last “ground floor” looks at a coronavirus stock before a pending breakout
- Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) already has a proven drug that has a strong safety history and was developed by one of the top names in biotech, Sanofi.
- Not only has it been presented to the US FDA, but Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has been working to advance Ifenprodil into multiple phase 2 human trials in Australia, Canada, and South Korea.
- Algernon Pharmaceuticals Inc. (OTC: AGNPF) (CSE: AGN) has already received positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial
- While early names have gone to trade much higher, the next round of coronavirus stocks could be offering immediate opportunity, now.